Porcine Matrix extracellular phosphoglycoprotein ELISA, MEPE
- Known as:
- Porcine Matrix extracellular phosphoglycoprotein Enzyme-linked immunosorbent assay test, MEPE
- Catalog number:
- E07M0259
- Product Quantity:
- 96 Tests/kit
- Category:
- -
- Supplier:
- BGene
- Gene target:
- Porcine Matrix extracellular phosphoglycoprotein ELISA MEPE
Related genes to: Porcine Matrix extracellular phosphoglycoprotein ELISA, MEPE
- Gene:
- MEPE NIH gene
- Name:
- matrix extracellular phosphoglycoprotein
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 4q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2000-09-19
- Date modifiied:
- 2016-10-05
Related products to: Porcine Matrix extracellular phosphoglycoprotein ELISA, MEPE
Related articles to: Porcine Matrix extracellular phosphoglycoprotein ELISA, MEPE
- Wound healing is a complicated process, so it's critical to identify efficient ways to hasten recovery. Platelet-rich plasma (PRP) and zinc oxide nanoparticles (ZnO NPs) have demonstrated potential in improving cutaneous wound healing in a variety of species. But little is known about their combined effects, especially in dogs. Therefore, this study determined how topical infiltration of PRP and ZnO NPs ointment, both separately and in combination, affect the healing of dogs' cutaneous wounds. Thirty-six full skin wounds were induced in the chest of six adult mongrel dogs. These wounds were randomly divided into six equal groups (6 wounds each) according to treatment protocol: group 1 served as a control and the wounds were dressed daily with normal saline only, group 2: the wounds were dressed daily with lanolin only, group 3: the wounds were infiltrated once with PRP, group 4: the wounds were treated with PRP single infiltration combined with lanolin ointment daily dressing, group 5: the wounds were dressed daily with ZnO NPs ointment, and group 6: the wounds were infiltrated once with PRP and daily dressed with ZnO NPs ointment. Wound healing progress was monitored; epithelialization, wound contraction, and overall healing were assessed. Total antioxidant capacity (TAC), malondialdehyde (MDA) and the concentration of platelets derived growth factor beta (PDGFβ) were measured on wound fluid. Gene expression of matrix extracellular phosphoglycoprotien (MEPE), transforming growth factor beta (TGF-β) and tumor necrosis factor alpha (TNF-α) were also evaluated on skin biopsies at day 0, 5, 10 and 20. Histopathology, immunohistochemistry and staining of collagen bundles were performed on skin biopsies at 5, 10 and 20 days of wound induction. All data were statistically analyzed. There was a significant interaction between the group and time across all parameters (P < 0.001). The PRP-ZnO NPs group consistently has a great effect on wound size reduction, contraction, healing, epithelialization, and antioxidant activity, along with higher MEPE and PDGFβ expression and arranged parallel collagen bundles, indicating enhanced regeneration. While PRP alone showed the strongest TGF-β increase and anti-inflammatory effect (lowest TNF-α). PRP-ZnO NPs provided the best overall balance between regeneration and inflammation control. All treatments surpassed the control and lanolin groups, which showed minimal improvement. PRP-Lanolin and ZnO NPs offered moderate benefits but were less effective than PRP-ZnO NPs or PRP. ZnO NPs and PRP work together to improve skin wound healing in dogs; PRP promotes regenerative signaling, while ZnO NPs reduce oxidative stress and microbial load. - Source: PubMed
Publication date: 2026/06/02
Wafy Mona NHassan Elham ASaeed SamarKhattab Marwa SAbuBakr Huda OAbu-Seida Ashraf M - The mechanisms underlying sex differences in calcific aortic valve stenosis (CAVS) are poorly understood. We aimed to uncover sex-specific gene expression signatures of CAVS, including genes located on sexual chromosomes. - Source: PubMed
Publication date: 2026/05/22
Houessou UrsulaZamani PardisManikpurage Hasanga DLi ZhonglinGaudreault NathalieDahmene ManelDagenais FrançoisCouture ChristianClavel Marie-AnnickPibarot PhilippeMathieu PatrickBossé YohanThériault Sébastien - Osteocytes play a major role in the regulation of bone remodelling and homeostatis and should therefore be more prominently incorporated into in vitro bone models. Bioprinting is a versatile method to generate spatially defined tissue-like structures, however bioprinting of osteocytes remains challenging due to their post-mitotic nature. This study therefore investigates the transition of primary human osteoblasts (hOB) into osteocytes in bioprinted constructs, with respect to bioink composition and growth factor supplementation. Osteocytes were successfully differentiated from hOB, within bioprinted constructs via using alginate/methylcellulose/gelatin ink, alginate/methylcellulose/egg white ink and alginate/methylcellulose/human plasma ink (Alg/MC/Pl). Osteocytic morphology and marker expression was confirmed by fluorescence microscopy and gene expression analysis. Moreover, a significant upregulation of late osteocytic markers (e.g. SOST and MEPE) was observed under low serum conditions (2%) compared with cultures maintained in 10 % fetal calf serum (FCS). Human platelet lysate (hPL), evaluated as an alternative to FCS, also demonstrated the capacity to support osteocyte differentiation. Furthermore, hPL was successfully used for hOB pre-differentiation. In the presence of 2 % hPL, a higher number of multinucleated osteoclasts along with an elevated activity of osteoclast-specific enzymes (tartrate-resistant acid phosphatase, cathepsin K and carbonic anhydrase 2) in comparison to 2 % FCS was observed. This high potential of hPL to support osteoclastogenesis opens the way for physiologically-relevant in vitro bone models comprising both osteocytes and osteoclasts. Indirect co-cultures of human osteoclasts and human osteocytes, bioprinted and differentiated in Alg/MC/Pl showed expression of all relevant osteoclast and osteocyte markers.
. - Source: PubMed
Publication date: 2026/05/27
Bernhardt AnneLiu SuihongKara Özenler AylinWirsig KatharinaGelinsky Michael - The increasing prevalence of bone-related diseases and the desire to improve patient outcomes are driving research into bone replacement materials that overcome the limits of current bone substitutes. Molybdenum (Mo) is a promising candidate as an implant and degradable bone replacement material because it combines three key properties: mechanical strength, biocompatibility, and resorbability. However, little is known about the cellular mechanisms induced by Mo on bone regeneration. This study exposed a complex in vitro bone model as quadruple culture with primary human osteoblasts, osteocytes, osteoclasts, and endothelial cells, to Mo powder extracts to understand cell-material interactions in a multicellular system. Extracts with a final concentration of 1 mM Mo in quadruple cultures induced osteogenic differentiation by stimulation of gene expression and ALP activity, and gene expression, as well as enhanced calcium deposition of osteoblasts. Furthermore, expression of osteoblasts increased significantly and network formation of HUVEC with stimulated expression occurred. However, CD31 () expression and endothelial network density were reduced, indicating a complex, mixed angiogenic response. In contrast, Mo inhibited osteoclast formation and slowed down osteocyte differentiation, reducing , , and gene expression. Additionally, the RANKL ()/OPG () ratio of osteocytes was shifted toward OPG after Mo treatment. Cellular effects are most likely caused by the presence of molybdate anions. In summary, Mo extracts stimulated early bone healing factors involved in osteogenesis, vascularization, and mineralization, while osteoclastogenesis was inhibited. These dual effects in vitro provide mechanistic evidence supporting the potential of Mo as a growth factor-free bone replacement material and establish a cellular foundation for further preclinical development. - Source: PubMed
Publication date: 2026/05/07
Wirsig KatharinaBernhardt Anne - The efficacy of current bone-targeting agents, notably bisphosphonates, in the treatment of bone metastases remains limited by their systemic toxicity and excessively long half-life. This study aims to develop bone-targeting agents inspired by osteotropic peptides involved in the bone mineralization process. These agents are intended to provide an innovative alternative to bisphosphonates for precision bone targeting. - Source: PubMed
Publication date: 2026/04/26
Jamous MazenRoether BarbaraMühlberg EricKleist ChristianKübelbeck ArminHaberkorn UweMier Walter